Qinlock?

Qinlock Overview

Qinlock, also known as tucatinib, is an oral, small-molecule tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) [1]. It is used in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive breast cancer [2].

Development History

Qinlock has been under development since the early 2010s. In 2018, the US FDA granted Qinlock orphan drug status for the treatment of gastric cancer and HER2-positive cancer [3]. In 2020, Qinlock was approved by the FDA for the treatment of metastatic HER2-positive breast cancer [4].

Patent Status

The patent status of Qinlock is an important consideration for manufacturers. According to DrugPatentWatch.com [5], the patent for Qinlock is currently valid until 2027, with a total of 19 patent applications filed worldwide. This has significant implications for biosimilar development, as any biosimilars would need to be approved before the patent expires.

Clinical Trials

Qinlock has been evaluated in several clinical trials, including the HER2CLIMB trial, which demonstrated improved progression-free survival in patients with HER2-positive metastatic breast cancer [6]. These results highlight the efficacy of Qinlock in treating HER2-positive breast cancer.

Pricing and Availability

Qinlock is available in the United States, Canada, and several other countries. The cost of Qinlock can vary depending on insurance coverage and location. According to some sources, Qinlock is priced around $9,000 per month [7].

Competitors

Qinlock competes with other targeted therapies for HER2-positive breast cancer, such as Nerlynx (neratinib) and Perjeta (pertuzumab) [8]. The choice of therapy will depend on individual patient needs and circumstances.

References

[1] https://www.drugpatentwatch.com/chemicals/tucatinib
[2] https://www.fda.gov/drugs/information-drug-class/treatments-gastric-and-breast-cancer
[3] https://www.drugpatentwatch.com/patent/US20180361014A1
[4] https://www.fda.gov/drugs/information-drug-class/treatments-gastric-and-breast-cancer
[5] https://www.drugpatentwatch.com/patent/US10787631B2
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431153/
[7] https://www.goodrx.com/cancer/drugs/qinlock-cost-side-effects
[8] https://www.drugs.com/drugs-by-ingredient-erived-from/n-eratinib (neratinib)
[9] https://www.medscape.com/viewarticle/936142 (pertuzumab)